Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30705410 | 0.91 | PTPN1 (0.78) | PTPN1PTPN2 | |
| SCHEMBL12009128 | 0.87 | PTPN1 (0.94) | PTPN1PTPN2 | |
| SCHEMBL12009130 | 0.87 | PTPN1 (0.98) | PTPN1PTPN2 | |
| SCHEMBL2896988 | 0.86 | PTPN1 (1.00) | PTPN1PTPN2 | |
| SCHEMBL2889362 | 0.86 | PTPN1 (0.92) | PTPN1PTPN2 | |
| Potassium SCHEMBL2889366 | 0.86 | PTPN1 (0.92) | PTPN1PTPN2 | |
| SCHEMBL30705409 | 0.83 | PTPN1 (0.76) | PTPN1PTPN2 | |
| SCHEMBL22893529 | 0.82 | PTPN2 (0.62) | PTPN1PTPN2 | |
| SCHEMBL30705406 | 0.82 | PTPN1 (0.79) | PTPN1PTPN2 | |
| SCHEMBL30705414 | 0.81 | PTPN1 (0.81) | PTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109694-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4720059-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12503464-B2 | 1,2,5-thiadiazolidin-3-one 1,1-dioxide containing compounds and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250296927-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2025-09-25 | — | — | US | disclosed |
| WO-2024243441-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2024-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109694-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CCR10, SLC11A2, MSR1 | PTPN1 749/4885PTPN2 608/4885 |
| US-12503464-B2 | 1,2,5-thiadiazolidin-3-one 1,1-dioxide containing compounds and uses thereof | BRCA1, STING1, IFNG | PTPN1 577/4885PTPN2 896/4885 |
| US-20250296927-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MYD88, TP53, NFATC1 | PTPN1 1146/4885PTPN2 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.